Company news: Amgen’s (AMGN) quarterly results exceed analysts’ expectations

Amgen (AMGN) reported Q1 FY2025 earnings of $4.90 per share (versus $3.96 per share in Q1 FY2024), beating analysts’ consensus estimate of $4.27 per share.

The company’s quarterly revenues amounted to $8.149 bln (+9.4% y/y), beating analysts’ consensus estimate of $8.058 bln.

The company also reaffirmed guidance for FY2025, seeing EPS of $20.00-$21.20 versus analysts’ consensus estimate of $20.66 and revenues of $34.3-$35.7 bln versus analysts’ consensus estimate of $35.1 bln.

AMGN rose to $287.94 (+1.47%) in pre-market trading.